 Liudmila Kulik
Concepts (243)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Complement 3d | 14 | 2017 | 142 | 1.790 |
Why?
| | Immunoglobulin M | 17 | 2023 | 288 | 1.670 |
Why?
| | Antibodies, Monoclonal | 10 | 2023 | 1524 | 1.170 |
Why?
| | Complement C3d | 5 | 2023 | 67 | 1.040 |
Why?
| | B-Lymphocytes | 12 | 2017 | 890 | 0.750 |
Why?
| | Receptors, Complement 3b | 4 | 2020 | 80 | 0.730 |
Why?
| | Reperfusion Injury | 7 | 2021 | 301 | 0.710 |
Why?
| | Glutamic Acid | 1 | 2023 | 252 | 0.670 |
Why?
| | Complement Activation | 11 | 2020 | 412 | 0.620 |
Why?
| | Epitopes | 9 | 2023 | 491 | 0.620 |
Why?
| | Antigen-Antibody Complex | 1 | 2019 | 72 | 0.610 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2019 | 240 | 0.510 |
Why?
| | Immune System Diseases | 1 | 2015 | 40 | 0.430 |
Why?
| | Arthritis, Experimental | 5 | 2020 | 143 | 0.430 |
Why?
| | Kidney Glomerulus | 4 | 2021 | 128 | 0.420 |
Why?
| | Autoantibodies | 7 | 2019 | 1498 | 0.370 |
Why?
| | Mice | 31 | 2023 | 18549 | 0.360 |
Why?
| | Annexin A4 | 2 | 2015 | 6 | 0.330 |
Why?
| | Models, Immunological | 1 | 2011 | 101 | 0.330 |
Why?
| | Antibody Formation | 4 | 2010 | 294 | 0.330 |
Why?
| | Kidney Diseases | 3 | 2023 | 421 | 0.320 |
Why?
| | Mice, Knockout | 15 | 2019 | 3147 | 0.320 |
Why?
| | Complement C3 | 7 | 2021 | 191 | 0.310 |
Why?
| | Animals | 36 | 2023 | 38331 | 0.310 |
Why?
| | Glomerulonephritis | 2 | 2023 | 45 | 0.300 |
Why?
| | Single-Chain Antibodies | 2 | 2020 | 18 | 0.270 |
Why?
| | Immunity, Innate | 4 | 2015 | 856 | 0.270 |
Why?
| | Mice, Inbred C57BL | 17 | 2020 | 6067 | 0.270 |
Why?
| | Glomerulosclerosis, Focal Segmental | 2 | 2021 | 43 | 0.260 |
Why?
| | Antibodies | 2 | 2017 | 402 | 0.240 |
Why?
| | Complement Factor H | 2 | 2018 | 80 | 0.230 |
Why?
| | Complement System Proteins | 2 | 2021 | 317 | 0.230 |
Why?
| | Sheep | 5 | 2015 | 874 | 0.200 |
Why?
| | Annexins | 1 | 2023 | 2 | 0.200 |
Why?
| | Racemethionine | 1 | 2023 | 3 | 0.200 |
Why?
| | Receptors, Antigen, B-Cell | 3 | 2011 | 135 | 0.200 |
Why?
| | Cell Differentiation | 4 | 2007 | 2060 | 0.200 |
Why?
| | Intestinal Mucosa | 1 | 2009 | 675 | 0.190 |
Why?
| | Complement C3b | 1 | 2023 | 30 | 0.190 |
Why?
| | Receptors, Complement | 3 | 2022 | 125 | 0.190 |
Why?
| | Immunity, Humoral | 2 | 2015 | 119 | 0.190 |
Why?
| | Immunoglobulin G | 5 | 2023 | 899 | 0.190 |
Why?
| | Antibody Specificity | 4 | 2021 | 185 | 0.190 |
Why?
| | Protein Multimerization | 2 | 2021 | 209 | 0.190 |
Why?
| | Foot-and-Mouth Disease | 1 | 2022 | 1 | 0.190 |
Why?
| | Foot-and-Mouth Disease Virus | 1 | 2022 | 1 | 0.190 |
Why?
| | Methionine | 1 | 2023 | 163 | 0.180 |
Why?
| | Antigens, CD19 | 2 | 2015 | 139 | 0.180 |
Why?
| | B-Lymphocyte Subsets | 3 | 2010 | 80 | 0.180 |
Why?
| | Complement Pathway, Classical | 1 | 2021 | 19 | 0.180 |
Why?
| | Erythrocytes | 4 | 2015 | 757 | 0.170 |
Why?
| | Nephrosis, Lipoid | 1 | 2021 | 11 | 0.170 |
Why?
| | Nephrotic Syndrome | 1 | 2021 | 43 | 0.170 |
Why?
| | Lymphocyte Activation | 4 | 2021 | 1143 | 0.170 |
Why?
| | Cardiolipins | 1 | 2021 | 82 | 0.170 |
Why?
| | Transplants | 1 | 2021 | 39 | 0.170 |
Why?
| | Synoviocytes | 1 | 2020 | 18 | 0.160 |
Why?
| | Disease Models, Animal | 5 | 2019 | 4605 | 0.160 |
Why?
| | Autoimmunity | 3 | 2019 | 927 | 0.160 |
Why?
| | Protein Processing, Post-Translational | 1 | 2023 | 478 | 0.160 |
Why?
| | Mice, Inbred MRL lpr | 1 | 2019 | 37 | 0.160 |
Why?
| | Mice, Transgenic | 7 | 2011 | 2196 | 0.150 |
Why?
| | Joints | 1 | 2020 | 109 | 0.150 |
Why?
| | Complement Inactivating Agents | 2 | 2021 | 74 | 0.150 |
Why?
| | Single Photon Emission Computed Tomography Computed Tomography | 1 | 2019 | 15 | 0.150 |
Why?
| | Iodine Radioisotopes | 1 | 2019 | 138 | 0.140 |
Why?
| | Cattle | 3 | 2022 | 1006 | 0.140 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2019 | 186 | 0.140 |
Why?
| | Mice, Inbred DBA | 4 | 2020 | 188 | 0.140 |
Why?
| | Clonal Anergy | 2 | 2011 | 55 | 0.140 |
Why?
| | Complement C4b-Binding Protein | 1 | 2017 | 4 | 0.140 |
Why?
| | Tetanus Toxin | 1 | 2017 | 6 | 0.140 |
Why?
| | Protein Binding | 3 | 2019 | 2276 | 0.130 |
Why?
| | Lung Injury | 1 | 2021 | 237 | 0.130 |
Why?
| | Antirheumatic Agents | 1 | 2020 | 303 | 0.130 |
Why?
| | Ligands | 1 | 2019 | 674 | 0.130 |
Why?
| | Lung Transplantation | 1 | 2021 | 336 | 0.130 |
Why?
| | Kidney | 3 | 2023 | 1496 | 0.130 |
Why?
| | Vaccines, Synthetic | 1 | 2017 | 140 | 0.130 |
Why?
| | Inflammation Mediators | 1 | 2019 | 512 | 0.120 |
Why?
| | Complement Pathway, Alternative | 2 | 2018 | 122 | 0.120 |
Why?
| | Models, Molecular | 1 | 2021 | 1603 | 0.120 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 99 | 0.120 |
Why?
| | Tuberculosis | 1 | 2019 | 289 | 0.120 |
Why?
| | Mycobacterium tuberculosis | 1 | 2019 | 335 | 0.110 |
Why?
| | Down-Regulation | 3 | 2015 | 641 | 0.110 |
Why?
| | Antigens | 2 | 2015 | 349 | 0.110 |
Why?
| | Self Tolerance | 1 | 2015 | 26 | 0.110 |
Why?
| | Endothelial Cells | 1 | 2021 | 874 | 0.110 |
Why?
| | Immunoglobulin D | 1 | 2015 | 31 | 0.110 |
Why?
| | Phospholipids | 2 | 2015 | 211 | 0.110 |
Why?
| | Myocardial Reperfusion | 1 | 2015 | 53 | 0.110 |
Why?
| | Lymphocyte Depletion | 2 | 2013 | 135 | 0.100 |
Why?
| | Antibodies, Bispecific | 1 | 2015 | 64 | 0.100 |
Why?
| | Myocardial Reperfusion Injury | 1 | 2015 | 139 | 0.100 |
Why?
| | Humans | 20 | 2023 | 144859 | 0.100 |
Why?
| | Peptide Fragments | 1 | 2017 | 706 | 0.100 |
Why?
| | Spinal Cord Injuries | 1 | 2017 | 241 | 0.100 |
Why?
| | Complement C1q | 1 | 2013 | 33 | 0.100 |
Why?
| | Cell Death | 1 | 2015 | 388 | 0.100 |
Why?
| | Complement Pathway, Mannose-Binding Lectin | 1 | 2013 | 23 | 0.100 |
Why?
| | Lymphocyte Count | 2 | 2011 | 169 | 0.090 |
Why?
| | Retinal Pigment Epithelium | 1 | 2013 | 80 | 0.090 |
Why?
| | Genes, RAG-1 | 1 | 2012 | 12 | 0.090 |
Why?
| | Immunosuppressive Agents | 2 | 2021 | 844 | 0.090 |
Why?
| | Craniocerebral Trauma | 1 | 2014 | 177 | 0.090 |
Why?
| | Head Injuries, Closed | 1 | 2012 | 50 | 0.090 |
Why?
| | Transplantation, Homologous | 1 | 2013 | 414 | 0.090 |
Why?
| | Cytokines | 1 | 2019 | 2100 | 0.090 |
Why?
| | Chromosomes, Artificial, Bacterial | 1 | 2011 | 20 | 0.080 |
Why?
| | Amidines | 1 | 2011 | 15 | 0.080 |
Why?
| | Ornithine | 1 | 2011 | 27 | 0.080 |
Why?
| | Peritoneum | 1 | 2011 | 45 | 0.080 |
Why?
| | Mice, Inbred BALB C | 3 | 2023 | 1272 | 0.080 |
Why?
| | Adaptive Immunity | 1 | 2012 | 171 | 0.080 |
Why?
| | Hydrolases | 1 | 2011 | 55 | 0.080 |
Why?
| | Injections | 1 | 2011 | 199 | 0.080 |
Why?
| | Biomarkers | 2 | 2019 | 4279 | 0.080 |
Why?
| | Transgenes | 1 | 2011 | 188 | 0.080 |
Why?
| | Acute Kidney Injury | 1 | 2018 | 851 | 0.080 |
Why?
| | Graft Rejection | 1 | 2013 | 538 | 0.080 |
Why?
| | Germinal Center | 3 | 2022 | 67 | 0.080 |
Why?
| | Female | 9 | 2023 | 78217 | 0.070 |
Why?
| | Peptides, Cyclic | 2 | 2011 | 276 | 0.070 |
Why?
| | Chronic Disease | 1 | 2015 | 1833 | 0.070 |
Why?
| | Heart Transplantation | 1 | 2015 | 733 | 0.070 |
Why?
| | Brain Ischemia | 1 | 2011 | 356 | 0.070 |
Why?
| | Organ Specificity | 3 | 2016 | 315 | 0.070 |
Why?
| | Enzyme Inhibitors | 1 | 2011 | 832 | 0.060 |
Why?
| | Inflammation | 2 | 2016 | 2911 | 0.060 |
Why?
| | Dendritic Cells, Follicular | 2 | 2022 | 7 | 0.060 |
Why?
| | Doxorubicin | 2 | 2023 | 399 | 0.060 |
Why?
| | Lymphoid Tissue | 1 | 2007 | 80 | 0.060 |
Why?
| | Extracellular Space | 1 | 2007 | 132 | 0.060 |
Why?
| | Lymphopenia | 2 | 2007 | 69 | 0.060 |
Why?
| | Kidney Transplantation | 1 | 2013 | 702 | 0.060 |
Why?
| | Rats | 1 | 2015 | 5632 | 0.060 |
Why?
| | Oxidative Stress | 1 | 2013 | 1379 | 0.060 |
Why?
| | Homeodomain Proteins | 3 | 2015 | 525 | 0.060 |
Why?
| | Cell Line | 3 | 2017 | 2911 | 0.060 |
Why?
| | Interferon-alpha | 1 | 2006 | 184 | 0.060 |
Why?
| | Signal Transduction | 2 | 2011 | 5277 | 0.060 |
Why?
| | Recombinant Fusion Proteins | 2 | 2020 | 685 | 0.060 |
Why?
| | Amino Acid Sequence | 1 | 2009 | 2149 | 0.060 |
Why?
| | Male | 12 | 2021 | 72189 | 0.050 |
Why?
| | Molecular Sequence Data | 1 | 2009 | 2914 | 0.050 |
Why?
| | Recombinant Proteins | 2 | 2021 | 1358 | 0.050 |
Why?
| | Stroke | 1 | 2011 | 1227 | 0.050 |
Why?
| | Agammaglobulinemia | 1 | 2002 | 35 | 0.050 |
Why?
| | Adjuvants, Immunologic | 2 | 2017 | 246 | 0.050 |
Why?
| | Brain | 1 | 2014 | 2934 | 0.040 |
Why?
| | Capsid Proteins | 1 | 2022 | 96 | 0.040 |
Why?
| | In Situ Nick-End Labeling | 2 | 2012 | 123 | 0.040 |
Why?
| | T-Lymphocytes | 2 | 2012 | 2045 | 0.040 |
Why?
| | Arthritis, Rheumatoid | 2 | 2011 | 1171 | 0.040 |
Why?
| | Molecular Docking Simulation | 1 | 2021 | 124 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2009 | 3633 | 0.040 |
Why?
| | Stem Cells | 1 | 2005 | 626 | 0.040 |
Why?
| | Thymocytes | 1 | 2020 | 34 | 0.040 |
Why?
| | Proteolysis | 1 | 2021 | 177 | 0.040 |
Why?
| | Structure-Activity Relationship | 1 | 2021 | 569 | 0.040 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2020 | 108 | 0.040 |
Why?
| | DNA | 1 | 2006 | 1430 | 0.040 |
Why?
| | Molecular Dynamics Simulation | 1 | 2021 | 264 | 0.040 |
Why?
| | Antibodies, Neutralizing | 1 | 2022 | 347 | 0.040 |
Why?
| | Lymphocytes | 1 | 2021 | 396 | 0.040 |
Why?
| | Spleen | 2 | 2013 | 518 | 0.040 |
Why?
| | Blotting, Western | 2 | 2012 | 1207 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2019 | 328 | 0.040 |
Why?
| | Protein Conformation | 1 | 2021 | 943 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2020 | 4177 | 0.030 |
Why?
| | Glomerulonephritis, Membranoproliferative | 1 | 2018 | 25 | 0.030 |
Why?
| | Aging | 1 | 2009 | 1980 | 0.030 |
Why?
| | Antibodies, Viral | 1 | 2022 | 686 | 0.030 |
Why?
| | Synovial Membrane | 2 | 2011 | 123 | 0.030 |
Why?
| | Apoptosis | 2 | 2020 | 2454 | 0.030 |
Why?
| | Immunohistochemistry | 2 | 2012 | 1734 | 0.030 |
Why?
| | Locomotion | 1 | 2017 | 104 | 0.030 |
Why?
| | Models, Animal | 1 | 2017 | 394 | 0.030 |
Why?
| | Genes, Synthetic | 1 | 2015 | 14 | 0.030 |
Why?
| | Time Factors | 3 | 2015 | 7107 | 0.030 |
Why?
| | Transplantation Tolerance | 1 | 2015 | 37 | 0.030 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2014 | 26 | 0.030 |
Why?
| | Albuminuria | 1 | 2015 | 188 | 0.030 |
Why?
| | fas Receptor | 1 | 2014 | 94 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2021 | 3628 | 0.020 |
Why?
| | Diagnostic Imaging | 1 | 2016 | 334 | 0.020 |
Why?
| | Complement C3-C5 Convertases | 1 | 2013 | 22 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2016 | 441 | 0.020 |
Why?
| | Surface Plasmon Resonance | 1 | 2013 | 91 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 242 | 0.020 |
Why?
| | Oxidants | 1 | 2013 | 104 | 0.020 |
Why?
| | Choroidal Neovascularization | 1 | 2013 | 57 | 0.020 |
Why?
| | Astrocytes | 1 | 2014 | 223 | 0.020 |
Why?
| | Rituximab | 1 | 2013 | 211 | 0.020 |
Why?
| | Microglia | 1 | 2014 | 268 | 0.020 |
Why?
| | Protein-Arginine Deiminases | 1 | 2011 | 16 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2013 | 340 | 0.020 |
Why?
| | Collagen Type II | 1 | 2011 | 54 | 0.020 |
Why?
| | Blood-Brain Barrier | 1 | 2012 | 155 | 0.020 |
Why?
| | Citrulline | 1 | 2011 | 46 | 0.020 |
Why?
| | Myocardium | 1 | 2015 | 949 | 0.020 |
Why?
| | Lymphocyte Subsets | 1 | 2009 | 87 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2010 | 423 | 0.020 |
Why?
| | Vaccination | 1 | 2017 | 1423 | 0.020 |
Why?
| | Immunoglobulins | 1 | 2009 | 163 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 858 | 0.020 |
Why?
| | Immune System | 1 | 2009 | 182 | 0.020 |
Why?
| | Species Specificity | 1 | 2009 | 576 | 0.020 |
Why?
| | Receptors, HIV | 1 | 2007 | 24 | 0.020 |
Why?
| | Binding Sites, Antibody | 1 | 2007 | 41 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2009 | 321 | 0.020 |
Why?
| | Antibodies, Blocking | 1 | 2007 | 38 | 0.020 |
Why?
| | K562 Cells | 1 | 2007 | 95 | 0.020 |
Why?
| | Disease Progression | 1 | 2015 | 2881 | 0.020 |
Why?
| | Virion | 1 | 2007 | 115 | 0.020 |
Why?
| | Lupus Vulgaris | 1 | 2006 | 5 | 0.020 |
Why?
| | Antigen-Antibody Reactions | 1 | 2006 | 50 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2021 | 11581 | 0.020 |
Why?
| | HIV | 1 | 2007 | 248 | 0.010 |
Why?
| | Lung | 1 | 2019 | 4190 | 0.010 |
Why?
| | Cell Nucleus | 1 | 2009 | 619 | 0.010 |
Why?
| | Fibrinogen | 1 | 2006 | 180 | 0.010 |
Why?
| | Hyaluronan Receptors | 1 | 2005 | 104 | 0.010 |
Why?
| | Neurons | 1 | 2014 | 1645 | 0.010 |
Why?
| | Autoimmune Diseases | 1 | 2009 | 464 | 0.010 |
Why?
| | Young Adult | 1 | 2021 | 14033 | 0.010 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2005 | 366 | 0.010 |
Why?
| | Collagen | 1 | 2006 | 467 | 0.010 |
Why?
| | Erythrocyte Transfusion | 1 | 2005 | 228 | 0.010 |
Why?
| | Leukotriene B4 | 1 | 2002 | 37 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2011 | 2940 | 0.010 |
Why?
| | Crosses, Genetic | 1 | 2002 | 126 | 0.010 |
Why?
| | Up-Regulation | 1 | 2005 | 864 | 0.010 |
Why?
| | Lipopolysaccharides | 1 | 2005 | 875 | 0.010 |
Why?
| | Immunophenotyping | 1 | 2002 | 327 | 0.010 |
Why?
| | Aged | 1 | 2021 | 25822 | 0.010 |
Why?
| | Phenotype | 1 | 2009 | 3199 | 0.010 |
Why?
| | T-Lymphocyte Subsets | 1 | 2002 | 422 | 0.010 |
Why?
| | Intestines | 1 | 2002 | 358 | 0.010 |
Why?
| | Middle Aged | 1 | 2021 | 35939 | 0.010 |
Why?
| | Adult | 1 | 2021 | 40438 | 0.010 |
Why?
| | HIV Infections | 1 | 2007 | 3082 | 0.010 |
Why?
|
|
Kulik's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|